Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study

NeuroImage

Volumn 30, Issue 1, 2006, Pages 26-35

  Doudet, Doris J ^a   Rosa Neto, Pedro ^b   Munk, Ole L ^b   Ruth, Thomas J ^a   Jivan, Salma ^a   Cumming, Paul ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b AARHUS UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

11C methylphenidate; 11C dihydrotetrabenazine; 18F FDOPA; Monkey; MPTP; Parametric mapping; Parkinsonism; PET

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; CARBON 11; CATECHOLAMINE; DIHYDROTETRABENAZINE; DOPAMINE; FLUORODEOXYGLUCOSE F 18; LEVODOPA; METHYLPHENIDATE; TRACER;

AGE DISTRIBUTION; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MAPPING; BRAIN REGION; CATECHOLAMINERGIC SYSTEM; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DECARBOXYLATION; ENZYME SUBSTRATE; HYPOTHALAMUS; LIGAND BINDING; MONOAMINE NERVE CELL; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RHESUS MONKEY; SEROTONINERGIC NERVE; SEROTONINERGIC NERVE CELL; STATISTICAL SIGNIFICANCE; THALAMUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CAUDATE NUCLEUS; CORPUS STRIATUM; DOMINANCE, CEREBRAL; DOPA DECARBOXYLASE; DOPAMINE; MACACA FASCICULARIS; MACACA MULATTA; NERVE FIBERS; NEURONS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; REFERENCE VALUES; SEROTONIN; SUBSTANTIA NIGRA; SYNAPTIC VESICLES;

EID: 32644449962     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2005.09.044     Document Type: Article

References (83)

1. 11C-methylphenidate using ion exchange and C-18 Sep Paks J. Labelled Compd. Radiopharm. 40 1997 259
2. 3/KF or tetrabutylammonium fluoride as a base J. Labelled Compd. Radiopharm. 42 1999 S445 S446
3. K.J. Black, J.M. Koller, A.Z. Snyder, and J.S. Perlmutter Template images for nonhuman primate neuroimaging: 2. Macaque NeuroImage 14 3 2001 744 748
4. 11C]dihydrotetra-benzaine PET imaging in familial paroxysmal dystonic choreoathetosis Neurology 52 1999 1067 1069
5. W.D. Brown, M.D. Taylor, A.D. Roberts, T.R. Aokes, M.J. Schueller, J.E. Holden, L.M. Malischke, O.T. DeJesus, and R.J. Nickles FluoroDOPA PET shows nondopaminergic as well as dopaminergic destinations of levodopa Neurology 53 1999 1212 1218
6. M.G. Byas-Smith, J. Li, F. Szlam, D.C. Eaton, J.R. Votaw, and D.D. Denson Isofluorane induces dopamine transporter trafficking into the cell cytoplasm Synapse 53 2004 68 73
7. C.B. Calne, J.W. Langston, W.R. Martin, A.J. Stoessl, T.J. Ruth, M.J. Adam, B.D. Pate, and M. Schulzer Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease Nature 317 1985 246 248
8. R. Cash, T. Dennis, R. L'Heureux, R. Raisman, F. Javoy-Agid, and B. Scatton Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus Neurology 37 1987 42 46
9. 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects J. Nucl. Med. 40 1999 283 289
10. C.C. Chieuh, R.S. Burns, S.P. Markey, D.M. Jacobowitz, and I.J. Kopin Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys Life Sci. 36 1985 213 218
11. 3H]citalopram Neuroscience 54 1993 691 699
12. M. Cordes, B.J. Snow, S. Cooper, M. Schulzer, B.D. Pate, T.J. Ruth, and D.B. Clane Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren Ann. Neurol. 36 1994 667 670
13. P. Cumming, and A. Gjedde Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms Synapse 29 1998 37 61
14. P. Cumming, H. Kuwabara, A. Ase, and A. Gjedde Regulation of DOPA decarboxylase in brain of living rat J. Neurochem. 65 1995 1381 1390
15. 3H]DOPA in the telencephalon of the living rat Brain Res. 747 1997 60 69
16. P. Cumming, O.L. Munk, and D. Doudet Loss of metabolites from monkey striatum during PET with FDOPA Synapse 41 3 2001 212 218
17. 18F]fluorodopa/PET and histology of fetal mesencephalic dopaminergic grafts to the striatum of MPTP-poisoned minipigs Cell Transplant. 11 2002 733 746
18. R.J. D'Amato, R.M. Zweig, P.J. Whitehouse, G.L. Wenk, H.S. Singer, R. Mayeux, D.L. Price, and S.H. Snyder Aminergic systems in Alzheimer's disease and Parkinsons's disease Ann. Neurol. 22 1987 229 236
19. 11C]methylphenidate for studying presynaptic dopaminergic neuron with positron emission tomography J. Labelled Compd. Radiopharm. 34 1994 989 997
20. Y.S. Ding, J.S. Fowler, N.D. Volkow, J. Logan, S.J. Gatley, and Y. Sugano Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain J. Nucl. Med. 36 1995 2298 2305
21. 11C]d-threo and l-threo-methylphenidate in the human and baboon brain Psychopharmacology (Berl.) 131 1 1997 71 78
22. 3H]mazindol autradiography Brain Res. 504 1989 64 71
23. D.J. Doudet PET studies of the MPTP model of Parkinson's disease D.B. Calne S. Calne Parkinson's Disease Advances in Neurology 2001 Lippincott, Williams and Wilkins 187 195
24. 18F-l-dopa imaging of the dopamine neostriatal system in clinically normal MPTP-treated rhesus monkeys Exp. Brain Res. 78 1989 69 80
25. 18F-DOPA: interpretation and biological correlates in non-human primates Psychiatry Res. 45 1992 153 168
26. D.J. Doudet, J.E. Holden, S. Jivan, E.G. McGeer, and R.J. Wyatt In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism Synapse 38 2000 105 113
27. J.L. Eberling, K.S. Bankiewicz, P. Pivirotto, J. Bringas, K. Chen, D.P. Nowotnik, J.P. Steiner, T.F. Budinger, and W.J. Jagust Dopamine transporter loss and clinical changes in MPTP-lesioned primates Brain Res. 832 1999 184 187
28. J.L. Eberling, J.A. Roberts, S.E. Taylor, H.F. van Brocklin, J.P. O-Neil, and T.E. Nordahl No effect of age and estrogen on aromatic l-amino acid decarboxylase activity in rhesus monkey brain Neurobiol. Aging 23 2002 479 483
29. 125I]β-CIT SPECT in clinical practice J. Neurol. Neurosurg. Psychiatry 76: 2005 1211 1216
30. J.D. Elsworth, A.Y. Deutch, D.E. Redmond Jr., J.R. Sladek Jr., and R.H. Roth MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulated cortex of the primate Neurosci. Lett. 114 1990 316 322
31. M.E. Emborg, S.Y. Ma, E.J. Mufson, A.I. Levey, M.D. Taylor, W.D. Brown, J.E. Holden, and J.H. Kordower Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys J. Comp. Neurol. 401 1998 253 265
32. R.M. Ferris, F.L.M. Tang, and R.A. Maxwell A comparison of the capacities of enantiomers of amphetamine, deoxypipradol and methylphenidate to inhibit the uptake of tritiated cetecholamines into rat cerebral cortex slices, synpatosomal preparations of rat cerebral cortex, hypothalamus, and striatum, and into adrenergic nerves of the rat aorta J. Pharmacol. Exp. Ther. 181 1972 407 416
33. K.A. Frey, R.A. Koeppe, M.R. Kilbourn, T.M. Vander Borght, R.L. Albin, S. Gilman, and D.E. Kumar Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging Ann. Neurol. 40 1996 873 884
34. S.J. Gatley, D.F. Pan, R.Y. Chen, G. Chaturvedi, and Y.S. Ding Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters Life Sci. 58 1996 PL231 PL239
35. D.S. Goldstein, C.S. Holmes, R. Dendi, S.R. Bruce, and S.-T. Li Orthostatic hypertension from sympathetic denervation in Parkinson's disease Neurology 58 2002 1247 1255
36. N. Harada, S. Nishiyama, K. Satoh, D. Fukumoto, T. Kakiuchi, and H. Tsukaka Age-related changes in the striatal dopaminergic system in the living brain: a multiparametric PET study in conscious monkeys Synapse 45 2002 38 45
37. 18F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain Synapse 54 2004 37 45
38. 11C]DOPA in human studies with positron emission tomography J. Neural Transm. 86 1991 25 51
39. 18F]fluoro-l-DOPA metabolism in living human brain: a comparison of six analytical methods J. Cereb. Blood Flow Metab. 13 1993 57 69
40. 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease J. Neurol. Neurosrug. Psychiatry 66 1999 754 758
41. 11C]dihydro-tetrabenazine (DTBZ) Nucl. Med. Biol. 24 1997 197 199
42. 3H]WIN 35,428) accumulation in dopamine regions of monkey brain: comparison of a mature and an aged monkey Brain Res. 611 1993 322 325
43. L. Kerenyi, G.A. Ricaurte, D.J. Schretlen, U. McCann, J. Varga, W.B. Mathews, H.T. Ravert, R.F. Dannals, J. Hilton, D.F. Wong, and Z. Szabo Positron emission tomography of striatal serotonin transporters in Parkinson's disease Arch. Neurol. 60 2003 1223 1229
44. M.R. Kilbourn Long-term reproducibility of in vivo measures of specific binding of radioligands in brain Nucl. Med. Biol. 31 2004 591 595
45. S.J. Kish, X.H. Zhong, O. Hornykiewicz, and J.W. Haycock Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between post-mortem and positron emission tomography studies Ann. Neurol. 38 1995 260 264
46. 11C]dihydrotetrabenazine J. Cereb. Blood Flow Metab. 19 1999 1376 1384
47. R. Kuczenski, and D.S. Segal Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine J. Neurochem. 68 1997 2032 2037
48. 18F]fluorodopamine storage capacity J. Cereb. Blood Flow Metab. 2005 (electronic publication ahead of print)
49. H. Kuwabara, P. Cumming, Y. Yasuhara, G.C. Léger, M. Guttman, M. Diksic, A.C. Evans, and A. Gjedde Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease J. Nucl. Med. 36 7 1995 1226 1231
50. C.S. Lee, A. Samii, V. Sossi, T.J. Ruth, M. Schulzer, J.E. Holden, J. Wudel, P.K. Pal, R. de le Fuent-Fernandez, D.B. Calne, and A.J. Stoessl In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann. Neurol. 47 2000 493 503
51. C.S. Lee, M. Schulzer, R. de la Fuente-Fernandez, E. Mak, L. Kuramoto, V. Sossi, T.J. Ruth, D.B. Calne, and A.J. Stoessl Lack of regional selectivity during the progression of Parkinson's disease: implications for pathogenesis Arch. Neurol. 61 2004 1920 1925
52. K.G. Lloyd, and O. Hornykiewicz Occurence and distribution of aromatic l-amino acid (l-DOPA) decarboxylase in the human brain J. Neurochem. 19 1972 1549 1559
53. J. Logan, J.S. Fowler, N.D. Volkow, G.-J. Wang, Y.-S. Ding, and D.L. Alexoff Distribution volume ratios without blood sampling from graphic analysis of PET data J. Cereb. Blood Flow Metab. 16 1996 834 840
54. A.V.P. Mackay, P. Davies, A.J. Dewar, and C.M. Yates Regional distribution on enzymes associated with neurotransmission by monoamines, acetylcholine and GABA in the human brain J. Neurochem. 30 1978 827 839
55. R.M. Marie, L. Barre, P. Rioux, P. Allain, B. Lechevalier, and J.C. Baron PET imaging of neocortical monoaminergic terminals in Parkinson's disease J. Neural Transm.: Parkinson's Dis. Dementia Sect. 9 1995 55 71
56. I.J. Mitchell, A.J. Cross, M.A. Sambrook, and A.R. Crossman Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus Neurosci. Lett. 61 1985 195 200
57. I.J. Mitchell, A.J. Cross, M.A. Sambrook, and A.R. Crossman N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism J. Neural Transm., Suppl. 20 1986 41 46
58. 18F-DOPA PET study Brain Res. 982 2003 137 145
59. A.S. Nagano, K. Ito, T. Kato, Y. Arahata, T. Kachi, K. Hatano, Y. Kawasumi, A. Nakamura, T. Yamada, Y. Abe, and T. Ishigaki Extrastriatal mean regional uptake of fluorine-18-FDOPA in the normal aged brain. An approach using MRI-aided spatial normalization NeuroImage 11 2000 760 766
60. 18F]fluoro-l- dopa Appl. Radiat. Isot. 43 1992 989 996
61. C. Pifl, G. Schingnitz, and O. Hornykiewicz The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease Neurosci. Lett. 92 2 1988 228 233
62. C. Pifl, G. Schingnitz, and O. Hornykiewicz Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey Neuroscience 44 1991 591 605
63. P. Rosa-Neto, D.J. Doudet, and P. Cumming Gradients of dopamine D1 and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET NeuroImage 22 3 2004 1076 1083
64. O.G. Rousset, P. Deep, H. Kuwabara, A.C. Evans, A.H. Gjedde, and P. Cumming Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-l-dopa studied with PET in normal control and Parkinson's disease subjects Synapse 37 2 2000 81 89
65. M.F. Salvatore, S. Apparsundaram, and G.A. Gerhardt Decreased plasma membrane expression of striatal dopamine transporters in aging Neurobiol. Aging 24 2003 1147 1154
66. B. Scatton, F. Javoy-Agid, L. Rouquier, B. Dubois, and Y. Agid Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease Brain Res. 275 1983 321 328
67. K. Schannak, A. Rajput, B. Rozdilsky, S. Kish, J. Gilbert, and O. Hornykiewicz Noradrenaline, dopamine, and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects Brain Res. 639 1994 33 41
68. 125I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease Brain 128 2005 1605 1612
69. 3H]dihydrotetrabenazine binding sites in the mouse brain and its relationship to the distribution of monoamines and their metabolites Brain Res. 370 1986 176 181
70. 125I]β-CIT striatal uptake correlated with symptom severity in Parkinson's disease Ann. Neurol. 38 1995 589 598
71. S.K. Shahani, R. Lingamaneni, and H.C.Jr. Hemmings General anesthetic actions on norepinephrine, dopamine, and gamma-butyric acid transporters in stably transfected cells Anesth. Analg. 95 2002 893 899
72. B.J. Snow, F.J. Vingerhoets, J.W. Langston, J.W. Tetrud, V. Sossi, and D.B. Calne Pattern of dopamergic loss in the striatum of humans with MPTP-induced parkinsonism J. Neurol. Neurosurg. Psychiatry 68 2000 313 316
73. V. Sossi, J.E. Holden, G. Chan, M. Krzywinski, A.J. Stoessl, and T.J. Ruth Analysis of four different dopaminergic tracers using two different tissue input function methods J. Cereb. Blood Flow Metab. 20 2000 653 660
74. Sossi,V., McCormick, S., Kornelsen, R., Strome, E., Ruth, T.J., Doudet, D.J., in press. Effect of anesthesia on DTBZ and MP binding as evaluated by a Concord-CTI microPET imaging and post mortem measures. Mol. Imaging Biol.
75. 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease Acta Neurol. Scand. 77 1988 192 201
76. 123I]β-ICT SPECT J. Neurol. 245 1998 14 20
77. Torstensen, R., 1999. [PhD thesis] Functional regulation of the dopaminergic system in vivo. Uppsala University.
78. N.D. Volkow, Y.S. Ding, J.S. Fowler, G.J. Wang, J. Logan, S.J. Gatley, R. Hitzemann, G. Smith, S.D. Fields, and R. Gur Dopamine transporters decrease with age J. Nucl. Med. 37 1996 554 559
79. J. Votaw, M. Byas-Smith, J. Hua, R. Voll, L. Martarello, A.I. Levey, F.D. Bowman, and M.M. Goodman Interaction of isofluorane with the dopamine transporter Anesthesiology 98 2003 404 411
80. J.R. Votaw, M.G. Byas-Smith, R. Voll, R. Halkar, and M.M. Goodman Isofluorane alters the amount of dopamine transporter expressed in the plasma membrane in humans Anesthesiology 101 2004 1128 1135
81. F.J. Vingerhoets, B.J. Snow, J.W. Tetrud, J.W. Langston, M. Schulzer, and D.B. Calne Positron-emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions Ann. Neurol. 36 1994 765 770
82. A.A. Wilson, D.P. Johnson, D. Mozley, D. Hussey, N. Ginovart, J. Nobrega, A. Garcia, J. Meyer, and S. Houle Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter Nucl. Med. Biol. 30 2003 85 92
83. 11C]WIN 35,428 Synapse 15 1993 130 142